CU23031A1 - Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes - Google Patents

Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes

Info

Publication number
CU23031A1
CU23031A1 CU20020019A CU20020019A CU23031A1 CU 23031 A1 CU23031 A1 CU 23031A1 CU 20020019 A CU20020019 A CU 20020019A CU 20020019 A CU20020019 A CU 20020019A CU 23031 A1 CU23031 A1 CU 23031A1
Authority
CU
Cuba
Prior art keywords
mucosopt
immunopotentiator
hepatitis
virus
surface antigen
Prior art date
Application number
CU20020019A
Other languages
English (en)
Inventor
Mato Yadira Lobaina
Feyt Rolando Pajon
Zaldivar Regis Aleman
Gonzalez Verena Lucila Muzio
Rubido Julio Cesar Aguilar
Garcia Gretel Sardinas
Perez Enrique Iglesias
Nieto Gerardo Enrique Guillen
Noa Dioslaida Urquiza
Arias Eduardo Penton
Rando Eugenio Hardy
Obregon Julio Cesar Alvarez
Gonzalez Daymir Garcia
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU20020019A priority Critical patent/CU23031A1/es
Priority to KR10-2004-7011504A priority patent/KR20040081469A/ko
Priority to BRPI0307121-9A priority patent/BR0307121A/pt
Priority to PCT/CU2003/000001 priority patent/WO2003061692A2/es
Priority to CNA038026260A priority patent/CN1703241A/zh
Priority to EP03731653A priority patent/EP1493447A2/en
Priority to CA002471727A priority patent/CA2471727A1/en
Priority to US10/501,570 priority patent/US20050025780A1/en
Priority to ARP030100201A priority patent/AR038311A1/es
Priority to MYPI20030252A priority patent/MY141983A/en
Priority to ZA200405140A priority patent/ZA200405140B/en
Publication of CU23031A1 publication Critical patent/CU23031A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CU20020019A 2002-01-24 2002-01-24 Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes CU23031A1 (es)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CU20020019A CU23031A1 (es) 2002-01-24 2002-01-24 Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
KR10-2004-7011504A KR20040081469A (ko) 2002-01-24 2003-01-22 점막 면역 자극제로서 간염 비 바이러스 표면 항원 및결과물로서의 제제
BRPI0307121-9A BR0307121A (pt) 2002-01-24 2003-01-22 antìgeno de superfìcie do vìrus da hepatite b como um imunoestimulador da mucosa e as formulações resultantes
PCT/CU2003/000001 WO2003061692A2 (es) 2002-01-24 2003-01-22 Antígeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes.
CNA038026260A CN1703241A (zh) 2002-01-24 2003-01-22 乙型肝炎病毒表面抗原作为粘膜免疫刺激物和得到的制剂
EP03731653A EP1493447A2 (en) 2002-01-24 2003-01-22 Hepatitis b virus surface antigen as a mucosal immunostimulator and the resulting formulations
CA002471727A CA2471727A1 (en) 2002-01-24 2003-01-22 Hepatitis b virus surface antigen as a mucosal immunostimulator and the resulting formulations
US10/501,570 US20050025780A1 (en) 2002-01-24 2003-01-22 Hepatitis b virus surface antigen as a mucosal immunostimulator and the resulting formulations
ARP030100201A AR038311A1 (es) 2002-01-24 2003-01-23 Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
MYPI20030252A MY141983A (en) 2002-01-24 2003-01-24 Hepatitis b virus surface antigen as a mucosal immunoenhancer, resulting formulations
ZA200405140A ZA200405140B (en) 2002-01-24 2004-06-28 Hepatitus B virus surface antigen as a mucosal immunostimulator andthe resulting formulations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20020019A CU23031A1 (es) 2002-01-24 2002-01-24 Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes

Publications (1)

Publication Number Publication Date
CU23031A1 true CU23031A1 (es) 2005-02-23

Family

ID=27587819

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20020019A CU23031A1 (es) 2002-01-24 2002-01-24 Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes

Country Status (11)

Country Link
US (1) US20050025780A1 (es)
EP (1) EP1493447A2 (es)
KR (1) KR20040081469A (es)
CN (1) CN1703241A (es)
AR (1) AR038311A1 (es)
BR (1) BR0307121A (es)
CA (1) CA2471727A1 (es)
CU (1) CU23031A1 (es)
MY (1) MY141983A (es)
WO (1) WO2003061692A2 (es)
ZA (1) ZA200405140B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23405A1 (es) * 2003-10-20 2009-08-04 Ct Ingenieria Genetica Biotech Composiciones farmacéuticas para uso terapéutico
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
US9486515B2 (en) 2005-06-27 2016-11-08 Glaxosmithkline Biologicals S.A. Immunogenic composition
CN104958759B (zh) * 2015-06-24 2018-04-27 康希诺生物股份公司 多价脑膜炎球菌制剂盒、疫苗制剂及其制备方法
AU2017321863B2 (en) 2016-09-02 2024-07-11 Sanofi Vaccines US Inc. Neisseria meningitidis vaccine
MX2020001226A (es) * 2017-08-10 2020-07-20 Yisheng Biopharma Singapore Pte Ltd Una composicion para tratar y/o prevenir la infeccion por el virus de la hepatitis b y su metodo.
WO2019070019A1 (ja) * 2017-10-05 2019-04-11 東興薬品工業株式会社 経鼻ｂ型肝炎ワクチン組成物およびその製造方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4547368A (en) * 1983-12-20 1985-10-15 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Hepatitis B core antigen vaccine made by recombinant DNA
JP3626996B2 (ja) * 1992-05-23 2005-03-09 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム Ｂ型肝炎表面抗原および他の抗原からなる複合ワクチン
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
GB9503863D0 (en) * 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions
CU22629A1 (es) * 1997-03-06 2000-12-22 Ct Ingenieria Genetica Biotech Formulaciones inmunopotenciadoras para uso vacunal
CU22871A1 (es) * 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal

Also Published As

Publication number Publication date
MY141983A (en) 2010-08-16
CN1703241A (zh) 2005-11-30
AR038311A1 (es) 2005-01-12
ZA200405140B (en) 2006-07-26
KR20040081469A (ko) 2004-09-21
WO2003061692A3 (es) 2004-10-21
BR0307121A (pt) 2006-04-11
US20050025780A1 (en) 2005-02-03
WO2003061692A2 (es) 2003-07-31
EP1493447A2 (en) 2005-01-05
CA2471727A1 (en) 2003-07-31

Similar Documents

Publication Publication Date Title
NL1022738A1 (nl) Stofzuiger.
NL1022601A1 (nl) Stofzuiger.
IS8476A (is) Lifrarbólgu C-veirutálmar
IS8475A (is) Lifrarbólgu C-veirutálmar
DK1716162T3 (da) Phosphonater, amidomonophosphonater, amidobisphosphonater til behandling af virussygdomme
EP1603590A4 (en) INFLUENZA VIRUS VACCINE
NO20021431D0 (no) Intranasal influensavirusvaksine
DE60334381D1 (de) Staubsauger
PL372937A1 (en) Viral antigens
GB0206359D0 (en) Viral antigens
DE60227532D1 (de) Staubsauger
DK1523329T3 (da) Viruspartikeladjuvant
AU2003206862A8 (en) Hepatitis b vaccines
ITMO20030012A0 (it) Aspirapolvere perfezionato.
ES2417019T8 (es) Procedimiento de caracterización del virus de la enfermedad de la bursitis infecciosa
AU2003282498A8 (en) Hiv vaccine formulations
AU2003301850A8 (en) Hiv vaccine
CU23031A1 (es) Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
ATE392903T1 (de) Impfstoff gegen pferdeherpesvirus
IS7775A (is) DNA bóluefni sem umritar að minnsta kosti tvö óformgerð árprótín af vörtuveiru
PL372453A1 (en) An infectious bursal disease virus variant
WO2006019841A3 (en) Treatment of viral infections with egr 1 activators
AU2003210123B2 (en) Hepatitis B virus surface antigen as a mucosal immunostimulator and the resulting formulations
AU2003210123A1 (en) Hepatitis B virus surface antigen as a mucosal immunostimulator and the resulting formulations
SE0202122D0 (sv) Dammsugaremunstycke